Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.
J Comp Eff Res. 2022 Nov;11(16):1173-1184. doi: 10.2217/cer-2022-0111. Epub 2022 Sep 23.
J Comp Eff Res. 2022.
PMID: 36148923
Free article.
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Pérez-Cabeza AI, Manuel Vázquez Rodríguez J, Ràfols Priu C, Anguita Sánchez M, Lip GYH, Marin F.
Esteve-Pastor MA, et al.
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060.
Eur Heart J Cardiovasc Pharmacother. 2022.
PMID: 36318457
Item in Clipboard
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.
Marín F, Fernández MS, Barón-Esquivias G, Barrios V, Lekuona I, Pérez-Cabeza AI, Masjuan J, Del Vigo ER, Vázquez Rodríguez JM, Freixa-Pamias R, Schilling VR, Arribas F, Priu CR, Sánchez MA.
Marín F, et al. Among authors: priu cr.
J Comp Eff Res. 2023 Mar;12(3):e220049. doi: 10.57264/cer-2022-0049. Epub 2023 Feb 7.
J Comp Eff Res. 2023.
PMID: 36749006
Free PMC article.
Item in Clipboard
Cite
Cite